Download from app store
We have detected that you are using an Ad Blocker.
PracticeUpdate is free to end users but we rely on advertising to fund our site. Please consider supporting PracticeUpdate by whitelisting us in your ad blocker.
We have sent a message to the email address you have provided, . If this email is not correct, please update your settings with your correct address.
The email address you provided during registration, , does not appear to be valid. Please update your settings with a valid address before to continue using PracticeUpdate.
Please provide your AHPRA Number to ensure that you are given the correct level of access to our site.
featured

Journal Scan / Research · November 17, 2016

Bevacizumab Plus Paclitaxel vs Placebo Plus Paclitaxel as First-Line Therapy for HER2-Negative Metastatic Breast Cancer

European Journal of Cancer

 

Additional Info

Disclosure statements are available on the authors' profiles:

European Journal of Cancer
Bevacizumab Plus Paclitaxel Versus Placebo Plus Paclitaxel as First-Line Therapy for HER2-Negative Metastatic Breast Cancer (MERiDiAN): A Double-Blind Placebo-Controlled Randomised Phase III Trial With Prospective Biomarker Evaluation
Eur. J. Cancer 2016 Nov 04;[EPub Ahead of Print], D Miles, D Cameron, I Bondarenko, L Manzyuk, JC Alcedo, RI Lopez, SA Im, JL Canon, Y Shparyk, DA Yardley, N Masuda, J Ro, N Denduluri, S Hubeaux, C Quah, C Bais, J O'Shaughnessy

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.

Further Reading